367 related articles for article (PubMed ID: 25573268)
1. Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.
McGann S; Horton ER
Ann Pharmacother; 2015 Apr; 49(4):469-76. PubMed ID: 25573268
[TBL] [Abstract][Full Text] [Related]
2. Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary.
Kluetz PG; Pierce W; Maher VE; Zhang H; Tang S; Song P; Liu Q; Haber MT; Leutzinger EE; Al-Hakim A; Chen W; Palmby T; Alebachew E; Sridhara R; Ibrahim A; Justice R; Pazdur R
Clin Cancer Res; 2014 Jan; 20(1):9-14. PubMed ID: 24190979
[TBL] [Abstract][Full Text] [Related]
3. Alpha-emitter radium-223 in the management of solid tumors: current status and future directions.
Nilsson S
Am Soc Clin Oncol Educ Book; 2014; ():e132-9. PubMed ID: 24857093
[TBL] [Abstract][Full Text] [Related]
4. Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective.
Shore ND
Urology; 2015 Apr; 85(4):717-24. PubMed ID: 25681834
[TBL] [Abstract][Full Text] [Related]
5. Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases.
Shirley M; McCormack PL
Drugs; 2014 Apr; 74(5):579-86. PubMed ID: 24610703
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.
Hoskin P; Sartor O; O'Sullivan JM; Johannessen DC; Helle SI; Logue J; Bottomley D; Nilsson S; Vogelzang NJ; Fang F; Wahba M; Aksnes AK; Parker C
Lancet Oncol; 2014 Nov; 15(12):1397-406. PubMed ID: 25439694
[TBL] [Abstract][Full Text] [Related]
7. Radium Ra 223 dichloride in castration-resistant prostate cancer.
Joung JY; Ha YS; Kim IY
Drugs Today (Barc); 2013 Aug; 49(8):483-90. PubMed ID: 23977665
[TBL] [Abstract][Full Text] [Related]
8. Practical guide to the use of radium 223 dichloride.
Den RB; Doyle LA; Knudsen KE
Can J Urol; 2014 Apr; 21(2 Supp 1):70-6. PubMed ID: 24775727
[TBL] [Abstract][Full Text] [Related]
9. Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.
Ryan CJ; Saylor PJ; Everly JJ; Sartor O
Oncologist; 2014 Oct; 19(10):1012-8. PubMed ID: 25232039
[TBL] [Abstract][Full Text] [Related]
10. Nursing management of patients with castration-resistant prostate cancer undergoing radium-223 dichloride treatment.
Delacruz A; Arauz G; Curley T; Lindo A; Jensen T
Clin J Oncol Nurs; 2015 Apr; 19(2):E31-5. PubMed ID: 25840395
[TBL] [Abstract][Full Text] [Related]
11. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
[TBL] [Abstract][Full Text] [Related]
12. Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.
Nilsson S
Expert Opin Drug Saf; 2015 Jul; 14(7):1127-36. PubMed ID: 26022669
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.
Sartor O; Hoskin P; Coleman RE; Nilsson S; Vogelzang NJ; Petrenciuc O; Staudacher K; Thuresson M; Parker C
Prostate; 2016 Jul; 76(10):905-16. PubMed ID: 27004570
[TBL] [Abstract][Full Text] [Related]
14. The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer.
Wilson JM; Parker C
Expert Rev Anticancer Ther; 2016 Sep; 16(9):911-8. PubMed ID: 27501059
[TBL] [Abstract][Full Text] [Related]
15. Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer.
Borsò E; Boni G; Galli L; Ricci S; Farnesi A; Mazzarri S; Cianci C; Mariani G; Falcone A
Future Oncol; 2015; 11(2):323-31. PubMed ID: 25075962
[TBL] [Abstract][Full Text] [Related]
16. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.
Sartor O; Coleman R; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Fosså SD; Chodacki A; Wiechno P; Logue J; Widmark A; Johannessen DC; Hoskin P; James ND; Solberg A; Syndikus I; Vogelzang NJ; O'Bryan-Tear CG; Shan M; Bruland ØS; Parker C
Lancet Oncol; 2014 Jun; 15(7):738-46. PubMed ID: 24836273
[TBL] [Abstract][Full Text] [Related]
17. [Alpha emitter radium-223 dichloride: new therapy in castration-resistant prostate cancer with symptomatic bone metastases].
Heinzer H; König F; Klutmann S
Urologe A; 2014 Apr; 53(4):519-23. PubMed ID: 24604017
[TBL] [Abstract][Full Text] [Related]
18. Radium-223 dichloride: a new paradigm in the treatment of prostate cancer.
Anido Herranz U; Fernández Calvo O; Afonso Afonso FJ; Rodríguez Martínez de Llano S; Lázaro Quintela M; León Mateos L; Vázquez Estévez S; Antón Aparicio LM
Expert Rev Anticancer Ther; 2015 Mar; 15(3):339-48. PubMed ID: 25555355
[TBL] [Abstract][Full Text] [Related]
19. Metabolism and pharmacokinetics of radium-223 in prostate cancer.
Yeku O; Slovin SF
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):843-9. PubMed ID: 25740232
[TBL] [Abstract][Full Text] [Related]
20. Dosing, administration, and safety of radium-223: How I do it.
Dan TD; Doyle L; Raval AJ; Pridjian A; Gomella LG; Den RB
Can J Urol; 2016 Jun; 23(3):8301-5. PubMed ID: 27347625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]